Premium
Serologic immunotherapy: Results and probable mechanism of action
Author(s) -
Order Stanley E.,
Kirkman Robert,
Knapp Robert
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197407)34:1<175::aid-cncr2820340127>3.0.co;2-f
Subject(s) - medicine , antiserum , serology , antigen , immunotherapy , cytotoxic t cell , ovarian carcinoma , spleen , cytotoxicity , regimen , immunology , antibody , ovarian cancer , immune system , cancer , biology , in vitro , biochemistry
A previous report demonstrated the therapeutic efficacy of a rabbit ovarian anti‐tumor serum (R.O.A.T.S.) in the serologic treatment of an experimental murine ovarian carcinoma. Purification of the tumor antigen led to production of a more purified tumor antiserum (SG200) which allows a multiple dose regimen without mortality. Cytotoxic testing of spleen and tumor cells with R.O.A.T.S., N.R.S., (normal rabbit serum), and SG200 antiserum reveal marked tumor cytotoxicity with R.O.A.T.S. and SG200 but not with N.R.S. When 10 6 tumor cells are inoculated and treatment is given on day one; days one and two; or days one, two, and three, control animals have 0% survival and treated animals 0%, 20%, and 20% survival for over 120 days. In a study with 10 4 tumor cells (to observe differences in multiple dose treatment) 10% survival is noted in untreated tumor controls and 60% survival in the group treated on days one and two; and 90% survival on days one, two, six, and seven. Purified tumor antiserum allows for treatment without mortality, successful multiple dose therapy, and a high degree of selective tumor specificity, thus approaching the specific targeting required. This is a model system which may find application in clinical practice.